<DOC>
	<DOCNO>NCT01087502</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability linagliptin ( 5 mg / daily ) compare placebo give 12 week drug naive previously treat type 2 diabetic patient moderate severe renal impairment insufficient glycaemic control . In addition safety patient population long term ( 40 week ) treatment comparison sulfonylurea drug ( glimepiride ) .</brief_summary>
	<brief_title>Safety Efficacy Linagliptin Type-2-diabetes Mellitus Patients With Moderate Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Type 2 diabetes mellitus 2 . GFR &lt; 60 ml/min 3 . HbA1c &gt; =7.0 % &lt; = 10 % 4 . Age &gt; = 18 year 5 . BMI &lt; =45 kg/m2 6 . Signed date write informed consent Exclusion criterion : 1 . Myocardial infarction , stroke TIA within 3 month prior inform consent 2 . Renal impairment require dialysis 3 . Bariatric surgery 4 . Impaired hepatic function 5 . Treatment glitazones , GLP1 analogues , DPP4 inhibitors 6 . Treatment antiobesity drug 7 . Treatment SU , glinides metformin 8 week prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>